ClinicalTrials.gg
CompletedNCT01246583Updated Jan 11, 2021Results posted

CP-690-550 Ointment For Chronic Plaque Psoriasis

A Phase 2 interventional study of CP-690,550 Ointment 1 and Vehicle 1 in Psoriasis, sponsored by Pfizer. Completed at 12 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-01-11.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing tofacitinib in Psoriasis — 4 open to participants now, 4 under way, 1 of them phase 3. tofacitinib · Psoriasis.

Enrollment
15th of 19
71 · median 135
Started
2011
with 2 others
Phase 2
6 of 19
none open now
Registered
6th of 19
by date
Lead sponsor
14 of 19
Pfizer

Among the 19 studies testing tofacitinib in Psoriasis, this one is the 15th largest by enrollment, is one of 3 that started in 2011, is one of 6 in phase 2, and was the 6th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 19 studies testing tofacitinib in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing tofacitinib in Psoriasis, or all of them as a file.
02

Study summary

The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.

03

Conditions studied

  • Psoriasis

Keywords

  • Multi Site
  • Randomized
  • Placebo Controlled
  • Double Blind
  • Parallel Group
  • chronic plaque psoriasis
  • topical treatment
  • skin diseases
  • papulosquamous
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mild to moderate chronic plaque psoriasis (psoriasis vulgaris), with the duration of at least 6 months;
  • A target plaque of at least 9 sq. cm.

Exclusion criteria

Exclusion Criteria:

  • Demonstrates "rebound" or "flare" of chronic plaque psoriasis;
  • Non plaque form of psoriasis;
  • Currently have or history of psoriatic arthritis;
  • Current drug induced psoriasis;
  • Currently on systemic therapy or was on systemic therapy for psoriasis within the previous 6 months;
  • Currently on phototherapy for psoriasis or was on phototherapy within the previous 3 months
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Treatment Group A

    Drug: CP-690,550 Ointment 1

  • Placebo comparator
    Treatment Group B

    Drug: Vehicle 1

  • Experimental
    Treatment Group C

    Drug: CP-690,550 Ointment 2

  • Placebo comparator
    Treatment Group D

    Drug: Vehicle 2

Interventions

  • 2% CP-690,550 Ointment 1 twice daily for 4 weeks

  • DrugVehicle 1

    Vehicle 1 twice daily for 4 weeks

  • 2% CP-690,550 Ointment 2 twice daily for 4 weeks

  • DrugVehicle 2

    Vehicle 2 twice daily for 4 weeks

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4

    Target plaque was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The individual signs severity sub scores were summed to calculate TPSS. The total score varied in increments of 1 and ranged from 1 to 12, with higher scores representing greater severity of psoriasis.

    Time frame: Baseline, Week 4

Secondary outcomes

  1. Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Weeks 1, 2 and 3

    Target plaque was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The individual signs severity sub scores were summed to calculate TPSS. The total score varied in increments of 1 and ranged from 1 to 12, with higher scores representing greater severity of psoriasis.

    Time frame: Baseline, Weeks 1, 2, 3

  2. Change From Baseline in Target Plaque Severity Score (TPSS) of Erythema, Induration and Scaling at Weeks 1, 2, 3 and 4

    Target plaque severity was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked.

    Time frame: Baseline, Weeks 1, 2, 3, 4

  3. Percentage of Participants With Treatment Area Overall Severity of Psoriasis Response of "Clear" (0) or "Almost Clear" (1)

    Treatment area overall severity of psoriasis is global consideration of the erythema, induration and scaling across all psoriatic lesions, rated separately over the treatment area according to a 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the treatment area overall severity of psoriasis score and category. Total possible score range: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.

    Time frame: Week 1, 2, 3, 4

  4. Percentage of Participants Achieving Decrease From Baseline of Greater Than or Equal to 2 Points in Treatment Area Overall Severity of Psoriasis Score

    Treatment area overall severity of psoriasis is global consideration of the erythema, induration and scaling across all psoriatic lesions, rated separately over the treatment area according to a 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the treatment area overall severity of psoriasis score and category. Total possible score: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.

    Time frame: Week 1, 2, 3, 4

  5. Percent Change From Baseline in Target Plaque Area at Week 1, 2, 3 and 4

    A tracing of the target plaque on transparent film was used to quantify the target plaque area. The target plaque area was calculated by image analysis (planimetry). At baseline, target plaque area was determined prior to randomization to confirm the target plaque size of at least 9 cm\^2.

    Time frame: Baseline, Week 1, 2, 3, 4

  6. Itch Severity Item (ISI)

    The severity of itch was assessed using a single-item Patient Reported Outcome (PRO). Participants were asked to assess their worst itching due to psoriasis at the treatment area over the past 24 hours on a numeric rating scale ranging from of 0-10 where, 0=no itching and 10=worst possible itching.

    Time frame: Baseline, Week 1, 2, 3, 4

  7. Change From Baseline in the Treatment Area Itch Severity Item (ISI) at Week 1, 2, 3 and 4

    The severity of itch was assessed using a single-item PRO. Participants were asked to assess their worst itching due to psoriasis at the treatment area over the past 24 hours on a numeric rating scale ranging from of 0-10 where, 0=no itching and 10=worst possible itching.

    Time frame: Baseline, Week 1, 2, 3, 4

  8. Percentage of Participants in Each Patient Satisfaction With Study Medication (PSSM) Response Category

    The PSSM evaluates overall participants satisfaction with the study treatment. Participants response evaluation was based on single 7-point item: 1=very satisfied, 2=somewhat satisfied, 3=slightly satisfied, 4=neither satisfied nor dissatisfied, 5=slightly dissatisfied, 6=somewhat dissatisfied, and 7=very dissatisfied.

    Time frame: Week 4

  9. Number of Participants With Administration Site Adverse Events

    An adverse event was any untoward medical occurrence attributed to study drug in a participant who received study drug. Application site adverse event included documentation of any clinically significant local reaction, e.g erosion, vesicles or scabbing.

    Time frame: Baseline up to follow up visit (Day 36-39 after last dose of study treatment) (up to maximum of 9.5 weeks)

  10. Number of Participants With Burning/Stinging of Psoriatic or Perilesional Skin in The Treatment Area

    Burning/stinging symptoms at the treatment area including target plaque, additional plaque/s within the treatment area (if any) and treated perilesional skin (if any) were queried from the participants and scored by the investigator using a 4-point scale: 0=none; 1=Mild; 2=Moderate; 3=Severe. Except at baseline pre-dosing, burning/stinging was assessed for 2 time periods based on the maximum burning or stinging that the participant has experienced: Immediate (within 5 minutes after application); Persistent (beyond 5 minutes after application).

    Time frame: Baseline, Week 1, 2, 3, 4

  11. Number of Participants With Draize Score of Perilesional Skin in The Treatment Area

    Draize scoring evaluated perilesional skin within treatment area for erythema and presence/absence of other signs and symptoms. Erythema score ranged from 0 to 4 as: 0(no reaction visible), 1(trace reactions- barely perceptible pinkness), 2(mild reaction- readily visible pinkness), 3(moderate reaction- definite redness), 4 (Strong to severe reaction- very intense redness). Letter grade defined as: J(Burning, stinging, itching), E(Edema), P(Papules), V(Vesicles), B(Bulla reaction), S(Spreading), W(Weeping), I(Induration), XC(Additional comments). Superficial observations defined as: G(Glazing), Y(Peeling), C(Scab), D(Hyperpigmentation), H(Hypopigmentation), F(Fissuring), R(Erosion), U(Ulceration), K(Scaling). Erythema and other signs/symptoms with at least 1 participant with Draize Score of Perilesional Skin in the treatment area were reported in this outcome measure.

    Time frame: Baseline, Week 1, 2, 3, 4

  12. Change From Baseline in Systolic and Diastolic Blood Pressure at Week 1, 2, 3, 4

    Blood pressure (BP) was measured in duplicate (approximately 5 minutes apart) using a standard calibrated BP measuring device. BP defined as pressure exerted by circulating blood upon walls of blood vessels. Diastolic BP is minimum pressure in arteries, near beginning of cardiac cycle when ventricles are filled with blood. Systolic BP is peak pressure in arteries, near end of the cardiac cycle when ventricles are contracting. Normal blood pressure is less than 120 millimeters of mercury (mmHg) systolic and less than 80 mmHg diastolic. Change=value at week 1, 2, 3, 4 minus value at baseline.

    Time frame: Baseline, Week 1, 2, 3, 4

  13. Change From Baseline in Heart Rate at Week 1, 2, 3, 4

    Heart (pulse) rate was measured in duplicate (approximately 5 minutes apart) for a minimum of 30 seconds. Heart rate is the number of heartbeats per unit of time, usually per minute. The heart rate is based on the number of contractions of the ventricles (the lower chambers of the heart). Change=value at week 1, 2, 3, 4 minus value at baseline.

    Time frame: Baseline, Week 1, 2, 3, 4

  14. Change From Baseline in Electrocardiogram (ECG) Findings at Week 4

    A single standard supine 12-lead Electrocardiogram (ECG) was performed after the participant had rested quietly for at least 10 minutes. ECG parameters included RR interval, PR interval, QRS complex, QT interval, QTcB (corrected for heart rate using Bazett's formula) interval, and QTcF (corrected for heart rate using Fridericia's formula) interval.

    Time frame: Baseline, Week 4

  15. Change From Baseline in Hemoglobin Level at Week 2, 4

    Time frame: Baseline, Week 2, 4

  16. Change From Baseline in Platelet and Neutrophil Count at Week 2, 4

    Time frame: Baseline, Week 2, 4

  17. Change From Baseline in Creatinine Level at Week 2, 4

    Time frame: Baseline, Week 2, 4

  18. Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Creatine Kinase (CK) Level at Week 2, 4

    Time frame: Baseline, Week 2, 4

  19. Plasma Concentration of CP-690,550

    Summary statistics were calculated by setting concentration values below the lower limit of quantification (lower limit of quantification=0.1 nanogram per milliliter \[ng/mL\]) to zero. Summary statistics were not presented if number of observations above lower limit of quantification (NALQ) = 0.

    Time frame: 0 (predose), 1, 2 and 4-9 hours postdose on Day 29 or early termination

07

Results

Posted Jan 11, 2021

Participant flow

Participant flow — Overall Study
Milestone2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Started23132510
Completed2213249
Not completed1011
Withdrew: Lost to follow-up0001
Withdrew: Protocol violation0010
Withdrew: Withdrawal by subject1000

Outcome measures

PrimaryPercent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4

Target plaque was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The individual signs severity sub scores were summed to calculate TPSS. The total score varied in increments of 1 and ranged from 1 to 12, with higher scores representing greater severity of psoriasis.

Time frame:
Baseline, Week 4
Reported as:
Mean · percent change
Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4
percent change2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4-53.97 ± 29.93-41.01 ± 20.29-24.26 ± 33.43-17.24 ± 25.40
SecondaryPercent Change From Baseline in Target Plaque Severity Score (TPSS) at Weeks 1, 2 and 3

Target plaque was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The individual signs severity sub scores were summed to calculate TPSS. The total score varied in increments of 1 and ranged from 1 to 12, with higher scores representing greater severity of psoriasis.

Time frame:
Baseline, Weeks 1, 2, 3
Reported as:
Mean · percent change
Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Weeks 1, 2 and 3
percent change2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Change at Week 1-31.00 ± 28.54-25.59 ± 18.98-12.65 ± 22.19-6.39 ± 23.06
Change at Week 2-46.32 ± 29.46-28.68 ± 20.72-17.26 ± 27.50-10.32 ± 26.53
Change at Week 3-49.90 ± 31.92-33.12 ± 18.92-26.32 ± 32.48-27.92 ± 19.07
SecondaryChange From Baseline in Target Plaque Severity Score (TPSS) of Erythema, Induration and Scaling at Weeks 1, 2, 3 and 4

Target plaque severity was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked.

Time frame:
Baseline, Weeks 1, 2, 3, 4
Reported as:
Mean · units on a scale
Change From Baseline in Target Plaque Severity Score (TPSS) of Erythema, Induration and Scaling at Weeks 1, 2, 3 and 4
units on a scale2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Baseline: Erythema2.52 ± 0.592.62 ± 0.512.44 ± 0.512.50 ± 0.53
Change at Week 1: Erythema-0.53 ± 0.77-0.77 ± 0.73-0.26 ± 0.62-0.11 ± 0.60
Change at Week 2: Erythema-0.90 ± 0.83-0.83 ± 0.58-0.42 ± 0.72-0.14 ± 0.69
Change at Week 3: Erythema-0.95 ± 0.90-1.00 ± 0.58-0.57 ± 0.87-0.75 ± 0.71
Change at Week 4: Erythema-1.14 ± 0.83-1.15 ± 0.69-0.61 ± 0.89-0.44 ± 0.88
Baseline: Induration2.52 ± 0.672.46 ± 0.522.28 ± 0.462.40 ± 0.52
Change at Week 1: Induration-0.68 ± 0.82-0.38 ± 0.77-0.17 ± 0.580.00 ± 0.50
Change at Week 2: Induration-1.05 ± 0.80-0.58 ± 0.79-0.33 ± 0.70-0.14 ± 0.38
Change at Week 3: Induration-1.18 ± 0.73-0.69 ± 0.63-0.57 ± 0.81-0.38 ± 0.74
Change at Week 4: Induration-1.27 ± 0.70-0.92 ± 0.64-0.43 ± 0.90-0.22 ± 0.67
Baseline: Scaling2.17 ± 0.652.23 ± 0.602.08 ± 0.492.30 ± 0.82
Change at Week 1: Scaling-0.95 ± 0.85-0.69 ± 0.48-0.48 ± 0.95-0.33 ± 0.71
Change at Week 2: Scaling-1.24 ± 0.83-0.75 ± 0.75-0.38 ± 0.77-0.43 ± 0.79
Change at Week 3: Scaling-1.27 ± 0.88-0.85 ± 0.99-0.67 ± 1.02-0.75 ± 0.71
Change at Week 4: Scaling-1.32 ± 0.89-1.00 ± 0.91-0.61 ± 1.03-0.56 ± 0.88
SecondaryPercentage of Participants With Treatment Area Overall Severity of Psoriasis Response of "Clear" (0) or "Almost Clear" (1)

Treatment area overall severity of psoriasis is global consideration of the erythema, induration and scaling across all psoriatic lesions, rated separately over the treatment area according to a 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the treatment area overall severity of psoriasis score and category. Total possible score range: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.

Time frame:
Week 1, 2, 3, 4
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Area Overall Severity of Psoriasis Response of "Clear" (0) or "Almost Clear" (1)
percentage of participants2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Week 142.1123.0821.7411.11
Week 252.3833.3329.1728.57
Week 359.0923.0838.1037.50
Week 463.6461.5439.1322.22
SecondaryPercentage of Participants Achieving Decrease From Baseline of Greater Than or Equal to 2 Points in Treatment Area Overall Severity of Psoriasis Score

Treatment area overall severity of psoriasis is global consideration of the erythema, induration and scaling across all psoriatic lesions, rated separately over the treatment area according to a 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the treatment area overall severity of psoriasis score and category. Total possible score: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.

Time frame:
Week 1, 2, 3, 4
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Decrease From Baseline of Greater Than or Equal to 2 Points in Treatment Area Overall Severity of Psoriasis Score
percentage of participants2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Week 115.790.000.000.00
Week 228.578.330.000.00
Week 331.8215.389.520.00
Week 436.3623.0817.390.00
SecondaryPercent Change From Baseline in Target Plaque Area at Week 1, 2, 3 and 4

A tracing of the target plaque on transparent film was used to quantify the target plaque area. The target plaque area was calculated by image analysis (planimetry). At baseline, target plaque area was determined prior to randomization to confirm the target plaque size of at least 9 cm\^2.

Time frame:
Baseline, Week 1, 2, 3, 4
Reported as:
Mean · percent change
Percent Change From Baseline in Target Plaque Area at Week 1, 2, 3 and 4
percent change2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Change at Week 1-14.26 ± 34.86-11.26 ± 28.55-3.72 ± 19.18-3.50 ± 7.32
Change at Week 2-22.67 ± 40.18-8.35 ± 37.19-5.52 ± 22.82-18.72 ± 22.18
Change at Week 3-36.21 ± 42.22-13.52 ± 42.92-4.90 ± 30.23-13.59 ± 38.56
Change at Week 4-38.39 ± 43.76-19.61 ± 49.93-8.71 ± 31.23-4.98 ± 27.05
SecondaryItch Severity Item (ISI)

The severity of itch was assessed using a single-item Patient Reported Outcome (PRO). Participants were asked to assess their worst itching due to psoriasis at the treatment area over the past 24 hours on a numeric rating scale ranging from of 0-10 where, 0=no itching and 10=worst possible itching.

Time frame:
Baseline, Week 1, 2, 3, 4
Reported as:
Mean · units on a scale
Itch Severity Item (ISI)
units on a scale2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Baseline4.09 ± 2.525.54 ± 3.104.36 ± 2.536.20 ± 2.62
Week 12.63 ± 2.544.69 ± 3.453.52 ± 2.744.22 ± 3.31
Week 22.24 ± 2.233.92 ± 3.123.42 ± 2.574.71 ± 3.15
Week 32.32 ± 2.423.69 ± 3.302.86 ± 2.593.50 ± 3.02
Week 41.55 ± 2.043.38 ± 2.902.30 ± 2.204.44 ± 2.88
SecondaryChange From Baseline in the Treatment Area Itch Severity Item (ISI) at Week 1, 2, 3 and 4

The severity of itch was assessed using a single-item PRO. Participants were asked to assess their worst itching due to psoriasis at the treatment area over the past 24 hours on a numeric rating scale ranging from of 0-10 where, 0=no itching and 10=worst possible itching.

Time frame:
Baseline, Week 1, 2, 3, 4
Reported as:
Mean · units on a scale
Change From Baseline in the Treatment Area Itch Severity Item (ISI) at Week 1, 2, 3 and 4
units on a scale2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Change at Week 1-1.47 ± 2.04-0.85 ± 1.63-0.74 ± 2.22-2.00 ± 3.74
Change at Week 2-1.90 ± 2.14-1.83 ± 3.24-1.00 ± 2.38-1.43 ± 3.87
Change at Week 3-1.86 ± 1.91-1.85 ± 2.79-1.62 ± 2.65-2.75 ± 4.17
Change at Week 4-2.64 ± 1.97-2.15 ± 2.85-2.13 ± 2.65-1.78 ± 3.87
SecondaryPercentage of Participants in Each Patient Satisfaction With Study Medication (PSSM) Response Category

The PSSM evaluates overall participants satisfaction with the study treatment. Participants response evaluation was based on single 7-point item: 1=very satisfied, 2=somewhat satisfied, 3=slightly satisfied, 4=neither satisfied nor dissatisfied, 5=slightly dissatisfied, 6=somewhat dissatisfied, and 7=very dissatisfied.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants in Each Patient Satisfaction With Study Medication (PSSM) Response Category
percentage of participants2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Very Satisfied50.023.132.00.0
Somewhat Satisfied18.238.520.011.1
Slightly Satisfied4.5012.011.1
Neither Satisfied nor Dissatisfied13.615.44.011.1
Slightly Dissatisfied004.00
Somewhat Dissatisfied4.57.712.022.2
Very Dissatisfied9.115.416.044.4
SecondaryNumber of Participants With Administration Site Adverse Events

An adverse event was any untoward medical occurrence attributed to study drug in a participant who received study drug. Application site adverse event included documentation of any clinically significant local reaction, e.g erosion, vesicles or scabbing.

Time frame:
Baseline up to follow up visit (Day 36-39 after last dose of study treatment) (up to maximum of 9.5 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Administration Site Adverse Events
Participants2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Number of Participants With Administration Site Adverse Events1000
SecondaryNumber of Participants With Burning/Stinging of Psoriatic or Perilesional Skin in The Treatment Area

Burning/stinging symptoms at the treatment area including target plaque, additional plaque/s within the treatment area (if any) and treated perilesional skin (if any) were queried from the participants and scored by the investigator using a 4-point scale: 0=none; 1=Mild; 2=Moderate; 3=Severe. Except at baseline pre-dosing, burning/stinging was assessed for 2 time periods based on the maximum burning or stinging that the participant has experienced: Immediate (within 5 minutes after application); Persistent (beyond 5 minutes after application).

Time frame:
Baseline, Week 1, 2, 3, 4
Reported as:
Count of participants · Participants
Number of Participants With Burning/Stinging of Psoriatic or Perilesional Skin in The Treatment Area
Participants2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Baseline: None, Immediate Stinging/Burning0000
Baseline: Mild, Immediate Stinging/Burning1021
Baseline: Moderate, Immediate Stinging/Burning0000
Baseline: Severe, Immediate Stinging/Burning0000
Baseline: None, Persistent Stinging/Burning0010
Baseline: Mild, Persistent Stinging/Burning1011
Baseline: Moderate, Persistent Stinging/Burning0000
Baseline: Severe, Persistent Stinging/Burning0000
Week 1: None, Immediate Stinging/Burning0001
Week 1: Mild, Immediate Stinging/Burning1200
Week 1: Moderate, Immediate Stinging/Burning0100
Week 1: Severe, Immediate Stinging/Burning0000
Week 2: None, Immediate Stinging/Burning0000
Week 2: Mild, Immediate Stinging/Burning1012
Week 2: Moderate, Immediate Stinging/Burning0001
Week 2: Severe, Immediate Stinging/Burning0000
Week 3: None, Immediate Stinging/Burning0000
Week 3: Mild, Immediate Stinging/Burning1010
Week 3: Moderate, Immediate Stinging/Burning0000
Week 3: Severe, Immediate Stinging/Burning0000
Week 4: None, Immediate Stinging/Burning0000
Week 4: Mild, Immediate Stinging/Burning1000
Week 4: Moderate, Immediate Stinging/Burning0000
Week 4: Severe, Immediate Stinging/Burning0000
Week 1: None, Persistent Stinging/Burning1200
Week 1: Mild, Persistent Stinging/Burning0100
Week 1: Moderate, Persistent Stinging/Burning0001
Week 1: Severe, Persistent Stinging/Burning0000
Week 2: None, Persistent Stinging/Burning1012
Week 2: Mild, Persistent Stinging/Burning0000
Week 2: Moderate, Persistent Stinging/Burning0001
Week 2: Severe, Persistent Stinging/Burning0000
Week 3: None, Persistent Stinging/Burning1010
Week 3: Mild, Persistent Stinging/Burning0010
Week 3: Moderate, Persistent Stinging/Burning0000
Week 3: Severe, Persistent Stinging/Burning0000
Week 4: None, Persistent Stinging/Burning1000
Week 4: Mild, Persistent Stinging/Burning0000
Week 4: Moderate, Persistent Stinging/Burning0000
Week 4: Severe, Persistent Stinging/Burning0000
SecondaryNumber of Participants With Draize Score of Perilesional Skin in The Treatment Area

Draize scoring evaluated perilesional skin within treatment area for erythema and presence/absence of other signs and symptoms. Erythema score ranged from 0 to 4 as: 0(no reaction visible), 1(trace reactions- barely perceptible pinkness), 2(mild reaction- readily visible pinkness), 3(moderate reaction- definite redness), 4 (Strong to severe reaction- very intense redness). Letter grade defined as: J(Burning, stinging, itching), E(Edema), P(Papules), V(Vesicles), B(Bulla reaction), S(Spreading), W(Weeping), I(Induration), XC(Additional comments). Superficial observations defined as: G(Glazing), Y(Peeling), C(Scab), D(Hyperpigmentation), H(Hypopigmentation), F(Fissuring), R(Erosion), U(Ulceration), K(Scaling). Erythema and other signs/symptoms with at least 1 participant with Draize Score of Perilesional Skin in the treatment area were reported in this outcome measure.

Time frame:
Baseline, Week 1, 2, 3, 4
Reported as:
Count of participants · Participants
Number of Participants With Draize Score of Perilesional Skin in The Treatment Area
Participants2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Baseline, Erythema: Moderate Reaction0010
Baseline, Letter Grade: Burning, Stinging, Itching2220
Baseline,Superficial Observation:Hyperpigmentation0010
Baseline,Superficial Observation: Scaling-Flacking0021
Baseline, Superficial Observation: Glazing0010
Week 1, Erythema: Trace Reaction0010
Week 1, Erythema: Moderate Reaction0010
Week 1, Letter Grade: Burning, Stinging, Itching1000
Week 1, Superficial Observation: Peeling1000
Week 1, Superficial Observation: Scaling-Flacking0020
Week 2, Erythema: Trace Reaction0020
Week 2, Letter Grade: Burning, Stinging, Itching0100
Week 2, Superficial Observation: Scaling-Flacking0010
Week 3, Erythema: Trace Reaction1000
Week 3, Letter Grade: Burning, Stinging, Itching0020
Week 4, Superficial Observation: Hyperpigmentation1000
SecondaryChange From Baseline in Systolic and Diastolic Blood Pressure at Week 1, 2, 3, 4

Blood pressure (BP) was measured in duplicate (approximately 5 minutes apart) using a standard calibrated BP measuring device. BP defined as pressure exerted by circulating blood upon walls of blood vessels. Diastolic BP is minimum pressure in arteries, near beginning of cardiac cycle when ventricles are filled with blood. Systolic BP is peak pressure in arteries, near end of the cardiac cycle when ventricles are contracting. Normal blood pressure is less than 120 millimeters of mercury (mmHg) systolic and less than 80 mmHg diastolic. Change=value at week 1, 2, 3, 4 minus value at baseline.

Time frame:
Baseline, Week 1, 2, 3, 4
Reported as:
Mean · mmHg
Change From Baseline in Systolic and Diastolic Blood Pressure at Week 1, 2, 3, 4
mmHg2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Baseline: Diastolic BP77.91 ± 9.8774.81 ± 9.6775.52 ± 8.6376.60 ± 10.86
Change at Week 1: Diastolic BP-3.18 ± 7.24-2.04 ± 7.17-2.54 ± 8.32-1.94 ± 7.28
Change at Week 2: Diastolic BP-1.86 ± 7.41-2.25 ± 5.89-3.63 ± 9.500.29 ± 5.80
Change at Week 3: Diastolic BP-2.23 ± 8.09-3.81 ± 9.04-0.26 ± 8.64-2.13 ± 8.70
Change at Week 4: Diastolic BP-2.16 ± 7.97-1.31 ± 6.94-2.61 ± 7.28-1.06 ± 6.58
Baseline: Systolic BP120.57 ± 14.83115.42 ± 12.77125.62 ± 16.26116.05 ± 15.85
Change at Week 1: Systolic BP-2.29 ± 8.483.58 ± 8.76-2.85 ± 8.203.39 ± 7.33
Change at Week 2: Systolic BP-2.24 ± 12.990.33 ± 7.24-3.67 ± 8.96-3.07 ± 5.99
Change at Week 3: Systolic BP-0.73 ± 12.140.65 ± 9.290.67 ± 8.62-0.81 ± 11.24
Change at Week 4: Systolic BP-0.55 ± 10.422.96 ± 9.73-5.07 ± 9.041.06 ± 9.33
SecondaryChange From Baseline in Heart Rate at Week 1, 2, 3, 4

Heart (pulse) rate was measured in duplicate (approximately 5 minutes apart) for a minimum of 30 seconds. Heart rate is the number of heartbeats per unit of time, usually per minute. The heart rate is based on the number of contractions of the ventricles (the lower chambers of the heart). Change=value at week 1, 2, 3, 4 minus value at baseline.

Time frame:
Baseline, Week 1, 2, 3, 4
Reported as:
Mean · beats per minute
Change From Baseline in Heart Rate at Week 1, 2, 3, 4
beats per minute2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Baseline67.24 ± 10.6466.77 ± 6.2466.12 ± 6.8273.75 ± 8.54
Change at Week 12.21 ± 9.293.12 ± 9.982.28 ± 8.316.39 ± 8.66
Change at Week 22.95 ± 10.752.71 ± 6.182.04 ± 7.910.36 ± 4.41
Change at Week 30.61 ± 7.962.27 ± 8.764.45 ± 12.412.50 ± 3.92
Change at Week 42.39 ± 7.732.85 ± 10.600.63 ± 7.08-2.00 ± 3.50
SecondaryChange From Baseline in Electrocardiogram (ECG) Findings at Week 4

A single standard supine 12-lead Electrocardiogram (ECG) was performed after the participant had rested quietly for at least 10 minutes. ECG parameters included RR interval, PR interval, QRS complex, QT interval, QTcB (corrected for heart rate using Bazett's formula) interval, and QTcF (corrected for heart rate using Fridericia's formula) interval.

Time frame:
Baseline, Week 4
Reported as:
Mean · milliseconds (msec)
Change From Baseline in Electrocardiogram (ECG) Findings at Week 4
milliseconds (msec)2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Baseline: RR Interval984.7 ± 165.17958.4 ± 120.78962.3 ± 111.02887.9 ± 124.81
Change at Week 4: RR Interval-47.7 ± 80.50-21.5 ± 114.31-23.1 ± 107.99-8.8 ± 78.53
Baseline: PR Interval165.3 ± 19.80163.8 ± 26.10159.0 ± 22.27170.4 ± 20.70
Change at Week 4: PR Interval-3.5 ± 11.892.0 ± 10.411.7 ± 16.734.2 ± 11.90
Baseline: QRS Complex92.8 ± 5.9493.8 ± 9.7895.3 ± 8.3893.0 ± 5.83
Change at Week 4: QRS Complex-1.5 ± 7.33-2.8 ± 9.11-1.3 ± 7.11-0.3 ± 9.45
Baseline: QT Interval400.2 ± 21.45400.1 ± 26.91411.1 ± 26.46392.3 ± 19.02
Change at Week 4: QT Interval-2.7 ± 11.40-1.2 ± 22.42-8.1 ± 27.362.9 ± 16.04
Baseline: QTcB Interval406.3 ± 24.59409.8 ± 18.53420.1 ± 19.96418.6 ± 26.88
Change at Week 4: QTcB Interval7.1 ± 16.835.8 ± 15.03-2.9 ± 19.775.4 ± 16.80
Baseline: QTcF Interval404.0 ± 17.23406.5 ± 18.16417.0 ± 19.39409.6 ± 20.03
Change at Week 4: QTcF Interval3.6 ± 12.883.0 ± 12.86-4.8 ± 19.624.3 ± 14.34
SecondaryChange From Baseline in Hemoglobin Level at Week 2, 4
Time frame:
Baseline, Week 2, 4
Reported as:
Mean · grams per deciliter (g/dL)
Change From Baseline in Hemoglobin Level at Week 2, 4
grams per deciliter (g/dL)2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Baseline14.56 ± 1.3413.68 ± 1.4114.21 ± 1.2613.90 ± 1.29
Change at Week 2-0.20 ± 0.590.12 ± 0.480.19 ± 0.52-0.06 ± 0.35
Change at Week 4-0.01 ± 0.56-0.08 ± 0.66-0.02 ± 0.49-0.09 ± 0.39
SecondaryChange From Baseline in Platelet and Neutrophil Count at Week 2, 4
Time frame:
Baseline, Week 2, 4
Reported as:
Mean · 10^3 per cubic millimeter (10^3/mm^3)
Change From Baseline in Platelet and Neutrophil Count at Week 2, 4
10^3 per cubic millimeter (10^3/mm^3)2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Baseline: Platelet227.30 ± 69.97212.85 ± 58.76233.68 ± 50.79214.90 ± 58.67
Change at Week 2: Platelet6.38 ± 20.886.85 ± 28.310.00 ± 21.3713.00 ± 15.68
Change at Week 4: Platelet1.05 ± 13.88-2.46 ± 15.33-7.30 ± 23.072.50 ± 12.65
Baseline: Neutrophil3.87 ± 1.363.75 ± 1.064.71 ± 1.043.79 ± 1.48
Change at Week 2: Neutrophil0.00 ± 0.590.00 ± 0.570.06 ± 0.880.23 ± 0.51
Change at Week 4: Neutrophil-0.01 ± 0.77-0.21 ± 0.41-0.34 ± 0.940.01 ± 0.57
SecondaryChange From Baseline in Creatinine Level at Week 2, 4
Time frame:
Baseline, Week 2, 4
Reported as:
Mean · milligram per deciliter (mg/dL)
Change From Baseline in Creatinine Level at Week 2, 4
milligram per deciliter (mg/dL)2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Baseline1.00 ± 0.220.89 ± 0.190.93 ± 0.140.89 ± 0.17
Change at Week 2-0.02 ± 0.06-0.01 ± 0.060.03 ± 0.07-0.04 ± 0.09
Change at Week 4-0.01 ± 0.06-0.01 ± 0.07-0.02 ± 0.07-0.00 ± 0.05
SecondaryChange From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Creatine Kinase (CK) Level at Week 2, 4
Time frame:
Baseline, Week 2, 4
Reported as:
Mean · international unit per liter (IU/L)
Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Creatine Kinase (CK) Level at Week 2, 4
international unit per liter (IU/L)2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
Baseline: AST24.57 ± 12.3522.77 ± 6.6923.04 ± 14.0421.10 ± 5.38
Change at Week 2: AST-2.00 ± 7.46-1.23 ± 3.831.84 ± 4.59-2.00 ± 3.57
Change at Week 4: AST-2.29 ± 7.18-1.08 ± 3.090.70 ± 5.980.63 ± 3.46
Baseline: ALT32.22 ± 26.7728.08 ± 16.0124.28 ± 17.8127.60 ± 13.37
Change at Week 2: ALT-4.48 ± 14.88-3.54 ± 4.772.12 ± 4.75-0.67 ± 7.00
Change at Week 4: ALT-5.76 ± 17.67-3.23 ± 5.450.61 ± 5.75-0.13 ± 1.96
Baseline: CK117.91 ± 67.38106.62 ± 73.11100.16 ± 61.2093.10 ± 32.29
Change at Week 2: CK-1.05 ± 40.05-11.00 ± 17.8813.00 ± 47.558.00 ± 56.44
Change at Week 4: CK4.14 ± 49.4919.62 ± 73.16-2.13 ± 25.91-6.88 ± 22.25
SecondaryPlasma Concentration of CP-690,550

Summary statistics were calculated by setting concentration values below the lower limit of quantification (lower limit of quantification=0.1 nanogram per milliliter \[ng/mL\]) to zero. Summary statistics were not presented if number of observations above lower limit of quantification (NALQ) = 0.

Time frame:
0 (predose), 1, 2 and 4-9 hours postdose on Day 29 or early termination
Reported as:
Mean · ng/mL
Plasma Concentration of CP-690,550
ng/mL2% CP-690,550 Ointment 12% CP-690,550 Ointment 2
0 hours0.1336 ± 0.14990.0313 ± 0.0742
1 hour0.1522 ± 0.18390.0434 ± 0.1083
2 hours0.1548 ± 0.20890.0570 ± 0.1459
4 hours0.1514 ± 0.22440.0553 ± 0.1420

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2% CP-690,550 Ointment 1—0/23 (0%)10/23 (43.5%)
Vehicle 1—0/13 (0%)3/13 (23.1%)
2% CP-690,550 Ointment 2—0/25 (0%)9/25 (36%)
Vehicle 2—0/10 (0%)3/10 (30%)
Most frequent other events
Showing 10 of 33
Most frequent other events
Event2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2
NasopharyngitisInfections and infestations1/230/132/251/10
PharyngitisInfections and infestations0/230/130/251/10
TonsillitisInfections and infestations0/230/130/251/10
Muscle strainInjury, poisoning and procedural complications0/230/130/251/10
ArthralgiaMusculoskeletal and connective tissue disorders0/230/130/251/10
Urinary tract infectionInfections and infestations1/231/130/250/10
Back painMusculoskeletal and connective tissue disorders0/231/130/250/10
PresyncopeNervous system disorders0/231/130/250/10
DyspepsiaGastrointestinal disorders1/230/130/250/10
Application site erythemaGeneral disorders1/230/130/250/10

Baseline characteristics

Age, Customized
Age, Customized(Participants)2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2Total
18 to 44 years755421
45 to 64 years12513636
Greater than or equal to 65 years437014
Sex: Female, Male
Sex: Female, Male(Participants)2% CP-690,550 Ointment 1Vehicle 12% CP-690,550 Ointment 2Vehicle 2Total
Female6810428
Male17515643
08

Study locations

12 sites
  • Horizon Research Group, Inc.
    Mobile, Alabama 36608, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Expresscare Medical
    Los Angeles, California 90045, United States
  • Park Avenue Dermatology, PA
    Orange Park, Florida 32073, United States
  • Skin Specialists, PC
    Omaha, Nebraska 68144, United States
  • Academic Dermatology Associates
    Albuquerque, New Mexico 87106, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Modern Research Associates, PLLC
    Dallas, Texas 75231, United States
  • K.Papp Clinical Research Inc.
    Waterloo, Ontario N2J 1C4, Canada
  • Innovaderm Research Inc
    Montreal, Quebec H2K 4L5, Canada
  • Siena Medical Research
    Montreal, Quebec H3Z 2S6, Canada
  • Centre de Recherche Dermatologique du Quebec metropolitain
    Quebec, G1V 4X7, Canada
09

References and documents

Publications

  • Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, Papp K. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013 Jul;169(1):137-45. doi: 10.1111/bjd.12266. PubMed 23387374 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2011 to primary completion in Nov 2011, 9 months.

Results were first posted in Jan 2021, 9 years 1 month after primary completion. A results delay was requested in Apr 2013.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 9 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2010
First posted
Nov 23, 2010
StartActual
Feb 16, 2011
Primary completionActual
Nov 29, 2011
CompletionActual
Nov 29, 2011
Results delay requested
Apr 9, 2013
Results first posted
Jan 11, 2021
Last update
Jan 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01246583
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 23, 2010
Start date
Feb 16, 2011
Primary completion
Nov 29, 2011
Completion
Nov 29, 2011
Results posted
Jan 11, 2021
Last update
Jan 11, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion